How Much Lower Can AstraZeneca plc Go?

Will AstraZeneca plc’s (LON:AZN) shares continue to fall?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m looking at some of the most popular companies in the FTSE 100 and wider market to try and establish which direction their shares are likely to move.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US) to ascertain if its share price will continue to fall.

Going it alone

When AstraZeneca revealed to the City that management was rejecting Pfizer’s increased offer of £55 per share, some shareholders celebrated but most vented their frustration at the decision.

Should you invest £1,000 in NatWest Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if NatWest Group made the list?

See the 6 stocks

AstraZeneca rejected the bid on the grounds that the takeover would pose a risk to the company’s pharmaceutical work, creating uncertainty for shareholders and workers. Management also stated that the price offered by Pfizer undervalued AstraZeneca as an independent science-led company.

AstraZeneca had previously stated that the minimum price it would be prepared to accept was £59 per share.

Unfortunately, as Pfizer has stated that its offer of £55 per share is “final”, due to City rules, the company cannot raise its offer again, unless there is a material change in circumstances. Pfizer is not allowed to approach with a higher offer for six months.

Short-term pain, long-term gain

AstraZeneca’s shares ended the trading day down 11% yesterday, after the buy-out rejection and it seems as if a lower share price is here to stay.

Indeed, AstraZeneca faces up to three years of shrinking earnings, before the company’s treatment pipeline starts to yield results.

Of course, this has angered many investors, as Pfizer’s offer would have meant that shareholders would have profited in the short term, without having to wait and see if the company can turn things around.  In particular, one top ten shareholder actually went so far as to call management’s rejection of the bid:

“…the single biggest case of value destruction on behalf of shareholders of all time…”

Still, over the long-term AstraZeneca’s gamble could pay off. The company’s management believes that the firm has the potential to grow sales to more than £27bn by 2023, 76% above the level reported for 2013.

This growth is expected to come from several key treatments, with heart drug Brilinta expected to produce sales of £2.1bn by 2023 and diabetes and respiratory medicines adding £4.7bn each.

Nevertheless, these growth forecasts do little to distract shareholders from the fact that AstraZeneca’s sales are not going to hit the level reported for 2013 until 2017 — that’s four years of waiting. 

Unfortunately, with earnings and sales set to fall, now the bid from Pfizer has been rejected, AstraZeneca should trade at a discount to its wider sector. So, as the biotechnology sector currently trades at an average historic P/E of 17 and AstraZeneca currently trades at a forward P/E of 17.1, the company’s current valuation seems about right.

However, AstraZeneca’s forward P/E is forecast to hit 17.2 by 2015, which makes the company look expensive and there is scope for the company’s share price to fall further if it fails to meet self-imposed growth targets. 

Foolish summary

So overall, now that AstraZeneca has rejected Pfizer’s offer, the company’s share price looks like it could fall much further as sales continue to slide. 

Should you invest £1,000 in NatWest Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if NatWest Group made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert does not own any share mentioned within this article.

More on Investing Articles

Hand is turning a dice and changes the direction of an arrow symbolizing that the value of an ETF (Exchange Traded Fund) is going up (or vice versa)
Investing Articles

This ETF has soared 40% in 2025! Is it a safe haven from stock market sell-offs?

An escalating US-China trade war means extreme stock market volatility may be here to stay. This ETF could be a…

Read more »

Investing Articles

Is it too late to buy this surging FTSE 100 stock?

Andrew Mackie believes that precious metals miners, long shunned by investors, are just beginning to emerge from a decade-long bear…

Read more »

Investing Articles

Down 50%, this penny stock could reward patient investors

A decision not to put the business up for sale, coupled with a poor harvest, has seen this penny stock…

Read more »

Investing Articles

Where next for the Tesla share price? 2025 is set to be a make or break year

The Tesla share price appears totally disconnected from the company’s valuation metrics, but that disconnect could finally end in 2025.

Read more »

Growth Shares

2 UK shares that could be significantly impacted by the new tariff rumours

Jon Smith talks about why the new US sector-specific probes could mean that some related UK shares could be under…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 UK dividend shares that look dirt cheap right now

With the US trade war sinking stock prices, there's a wealth of cheap opportunities in UK dividend shares now. Our…

Read more »

Investing Articles

Here are the latest forecasts for Lloyds shares out to 2027

Lloyds Bank shares are looking a bit shakier than they were just a couple of weeks ago. But what might…

Read more »

Investing Articles

2 beaten-down FTSE 100 growth shares that could stage explosive recoveries

The global fallout from Donald Trump's tariff war has left a number of the UK's biggest growth stocks trading on…

Read more »